Home
About Us
About Us
Board of Directors
Scientific Advisory Board
Management Team
Careers
For Researchers
Paxalisib
EVT801
Collaborating with Kazia
Publications and Presentations
For Partners
Our Current Partners
What We Are Looking For
For Patients
Accessing Kazia Drug Candidates in Clinical Trials
Accessing Kazia Drug Candidates for Compassionate Use
Resources for Patients
For Investors
Press Releases
ASX Announcements
Delisting from ASX
How to convert unlisted shares to ADSs
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Corporate Governance
Shareholder Services
Media Centre
Overview
Video
Coverage
Contact
Contact Us
Subscribe to email alerts
Heading &
Sub-heading can be edited through HQI
Home
>
For Investors
>
Press Releases
Press Releases
ASX Announcements
Delisting from ASX
How to convert unlisted shares to ADSs
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Corporate Governance
Shareholder Services
Press Releases
4-Nov-2024
Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme
2-Oct-2024
Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy at the American Society for Radiation Oncology 66th Annual Meeting
23-Sep-2024
Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium
12-Sep-2024
Kazia Executes Licensing Agreement with QIMR Berghofer
10-Jul-2024
Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma
27-Jun-2024
Kazia Announces Upcoming DIPG Data Presentations at ISPNO And Publication in European Journal of Cancer
2-May-2024
Kazia Reports Successful Stage 1 Completion Of The Evt801 Phase 1 Clinical Trial In Advanced Cancer Patients
21-Mar-2024
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases
14-Mar-2024
Kazia announces presentation of new data at AACR Annual Meeting
21-Feb-2024
Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint
19-Jan-2024
Kazia Continues Board Renewal With Two New Appointments
15-Jan-2024
Resignation of Chief Financial Officer; Appointment of Principal Accounting Officer and Principal Financial Officer
2-Dec-2023
Kazia Therapeutics Announces $2 Million Registered Direct Offering
1-Dec-2023
Kazia AGM - Chairman's Address
1-Dec-2023
Kazia 2023 Annual General Meeting R&D and Clinical Overview
1-Dec-2023
Kazia AGM Meeting results
29-Nov-2023
Kazia Announces Non-binding Letter of Intent for the Proposed Granting of Rights to Develop and Commercialize Paxalisib Outside of Oncology
21-Nov-2023
Kazia Provides Overview Of Paxalisib Related Presentations from the Society Of Neuro-oncology 2023 Annual Meeting
